ADMA Biologics is Thursday's pick for IBD 50 Growth Stocks To Watch. ADMA stock is building a cup base as the biotech has the ...

Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s ...

Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164 ...

Detailed price information for Adma Biologics (ADMA-Q) from The Globe and Mail including charting and trades.